In July, Kingsung Medical made consecutive appearances at the 9th Central China Cardiovascular Disease Conference (C4, Zhengzhou) and the 5th Beijing Structural Heart Disease Surgery Forum (SHSF 2026). The Company emerged as a focal point across both high-profile academic stages.

The headline exhibit, the Cortio™ Proximal Seal System, directly addresses a long-standing pain point in coronary artery bypass grafting (CABG). Featuring a proprietary umbrella-support architecture, the device enables proximal anastomosis without aortic cross-clamping. This fundamentally eliminates the risk of embolic dislodgement and aortic intimal injury inherent to conventional clamping—delivering an integrated advantage of safety, efficiency, and procedural simplicity. The booth drew on-site endorsements from leading cardiac surgeons from Fuwai Hospital, Beijing Anzhen Hospital and other top institutions, who recognized the system as a precise, clinically grounded solution to a persistent surgical challenge.

From Central China to the nation’s capital, the two back-to-back congresses served not merely as a showcase for domestic innovation, but as a tangible embodiment of clinician-engineer collaboration. Backed by 180+ granted patents and a newly closed over-100-million-RMB Series A financing round, Kingsung Medical stays firmly anchored to unmet clinical needs—translating more “China-originated” microsurgical and cardiac surgical solutions from the bench to the operating room. Making every procedure safer. Keeping every heartbeat steady.